

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**JACOBIO PHARMACEUTICALS GROUP CO., LTD.**

**加科思藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1167)**

**VOLUNTARY ANNOUNCEMENT  
JACOBIO RECEIVED US FDA INVESTIGATIONAL  
NEW DRUG CLEARANCE FOR P53 Y220C Activator JAB-30300**

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, the Food and Drug Administration of the United States (the “**FDA**”) has approved the Investigational New Drug (the “**IND**”) application of its self-developed drug JAB-30300 (P53 Y220C activator). Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the U.S., to evaluate safety and efficacy of JAB-30300. Jacobio also plans to submit IND application to the Center for Drug Evaluation of the National Medical Products Administration in China, and will conduct clinical studies in both China and the U.S. simultaneously once IND approval is received.

P53 is the single most frequently altered gene in human cancers, with mutations being present in approximately 50% patients with invasive tumors. JAB-30300 is an orally bioavailable small molecule activator for the treatment of patients with advanced or metastatic solid tumors harboring P53 Y220C mutation. JAB-30300 has shown very high binding affinity for P53 Y220C mutant proteins in studies. Tumor regression was achieved in multiple cancer models covering various tumor types, such as gastric cancer, ovarian cancer, breast cancer and lung cancer. The synergistic effect was found when JAB-30300 was combined with chemo or oncogenic protein inhibitors, which indicates a widely combinatorial potential of JAB-30300.

There is only one P53 Y220C activator program in the Phase I clinical stage globally. JAB-30300 is expected to be one of the first P53 Y220C activators to be approved.

## About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

**Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that JAB-30300 will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit [www.jacobiopharma.com](http://www.jacobiopharma.com) for more information.

By Order of the Board  
**JACOBIO PHARMACEUTICALS GROUP CO., LTD.**  
**Yinxiang WANG**  
*Chairman*

Hong Kong, March 1, 2024

*As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.*